Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer

Stopped Early termination due to significant lack of relevant patient data for evaluation of objectives.

Conditions

• Carcinoma, Ductal, Breast

Interventions

• PROCEDURE: Biopsy before and after three weeks of study treatment
• DRUG: paclitaxel
• DRUG: lapatinib
• DRUG: trastuzumab

Sponsor

West German Study Group

Collaborators

• [object Object]